INTRODUCTION
The role of gene regulation in obesity and its complications: introduction During the last two decades, the prevalence of obesity has increased to reach pandemic proportions and to produce a marked financial burden on health-care systems. According to conservative estimates, the economic costs of obesity range from 2 to 7% of the total health-care budgets in industrialized countries. Obesity provokes or aggravates several pathologies alone or in combination with other health problems. Obesity, in particular visceral obesity, is associated with the development of atherosclerotic cardiovascular disease, type 2 diabetes, hypertension, gallbladder disease, certain forms of cancer and respiratory diseases. The high prevalence of both obesity and its costly comorbidities have significantly contributed to intensify the efforts in obesity research, which is now at the forefront of biochemical, biomolecular and neurobiological research. In the last 10 y, the research has generated many important discoveries, which include those of adipose tissue-derived hormones such as leptin and adiponectin, those of the uncoupling proteins two (UCP2) and three (UCP3), and those of brain and gut peptides such as orexins, agoutirelated peptide and ghrelin. All these important discoveries were strongly related to the study of body weight regulation, which is central to the understanding of the etiology of obesity. Although obesity research has produced significant results, there are still tremendous efforts to pursue in order to elucidate the mechanisms through which obesity leads to health complications.
The Donald B Brown Research Chair on Obesity, the only Chair dedicated to obesity research in Canada, has held every year since its creation in 1997 a symposium entirely devoted to obesity research. In October 2001, when we organized instead a Continuing Medical Education formation session during the NAASO annual meeting held in Québec. The purpose of the yearly symposium is to summarize evidence regarding important topics related to obesity and propose novel obesity research directions. So far, six symposia have been organized. The first symposium of the series, entitled 'The Uncoupling Proteins and Obesity', It is within the mission of the Donald B Brown Research Chair on Obesity to provide continuing education about the best possible knowledge on obesity to scientists, physicians, health professionals, as well as to the public at large regarding the causes, the complications and the treatment of obesity.
Given the originality and importance of the research currently carried out on the regulation of gene expression to explain the mechanisms involved in the complication of obesity, an advisory committee to the Chair on the symposium series recommended to organize the present symposium on that important topic. The scientific program committee for this symposium, which was led by Denis Richard, included Yves Deshaies (Québec, QC, Canada), Frédéric Picard (Québec, QC, Canada) and Joel Berger (Rahway, NJ, USA). Paul Boisvert managed the logistics of the symposium.
The central role of PPARs and their specific control of target gene expression is each day challenged by the increasing clinical use of PPAR agonists to treat diabetes and atherosclerosis. For instance, it is of premium importance to understand the molecular physiology behind the PPARg mechanism of action, because on one hand PPARg agonism promotes adipogenesis and fat accumulation, and on the other hand obesity is a strong risk factor for atherosclerosis. Thus, questions like 'Should atherosclerotic and diabetic patients be treated with PPARg agonists?' prompt more fundamental research on gene regulation by PPARs and other nuclear receptors in their physiopathological context.
The present proceedings recapitulate the highlights of the fifth symposium of the DB Brown Obesity Research Chair, which was entitled, 'The Role of Gene Regulation in Obesity and its Complications'. The symposium was held on November 20, 2003, at Loews Le Concorde Hotel in Québec, QC, Canada. The first two sessions of the meeting were chaired by Dr Joel Berger. The first session addressed issues pertaining to the metabolic regulations modulated by PPARs and its coactivators. The second focused on the signaling factors mediating the metabolic effect of the PPARs. The last two sessions were chaired by Dr Frédéric Picard. One session was dedicated to the PPAR actions on the cardiovascular system, while the final session of the symposium concentrated on the novel modulators of adipocyte biology, including Foxo1 and SIR2.
In closing, our gratitude goes to all the invited experts, who not only presented authoritative and stimulating presentations but also participated with enthusiasm and competence in the lively discussion periods of the meeting. We would like to thank Joel Berger, and Frédéric Picard, who very skillfully chaired the meeting sessions and provided directions during the invigorating discussion periods. We would also like to acknowledge the contribution of the Centre de recherche sur le me´tabolisme e´nerge´tique (CREME) of the Université Laval for its support to the symposium. Finally, this symposium could not have taken place without the financial contribution from Merck Co, USA, and Hoffmann-La Roche, Canada.
